Introduction {#sec1-1}
============

India has one of the largest populations on the planet with a diverse set of social demographics. A seemingly small proportion (0.29%) of the population has been estimated to be living with human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS).([@ref1][@ref2]) However, the number is alarming and amounts to approximately 2.3 million people living with HIV/AIDS in India.([@ref2]) Combating the HIV/AIDS epidemic, to a large extent, has been possible due to advances in prevention and treatment of this disease. Advent of antiretroviral therapy (ART) has contributed to a significant change in the course of the disease, and the benefits of ART treatment are well documented.([@ref3][@ref4]) Among several factors that can affect the ART outcome, adherence to the ART has been cited as a major factor associated with poor outcomes.([@ref5][@ref6][@ref7]) For ART to have maximum effect, greater than 95% adherence has been suggested.([@ref4][@ref8]) Additionally, non-adherence to ART is a major cause of HIV drug resistance.([@ref4][@ref8]) Especially in the Indian context, adherence to ART is very important due to the sheer number of HIV/AIDS cases, the socioeconomic status, diversity of the population and regions. That is, the socioeconomic challenges faced by patients contribute to non-adherence to ART in India. For example, most individuals living with HIV/AIDS in India are poorly educated and may not value the importance of ART, especially when their health status improves.([@ref9]) As a result, some interrupt ART, restarting when adequate funding becomes available.([@ref10]) In some seroconcordant couples, the partner clinically needing ART is known to share their medication with their HIV-negative partner or spouse.([@ref9])

There have been several studies on ART adherence in India. However, results from these studies have shown varying estimates on ART adherence. While the study by Sarna *et al*.([@ref11]) demonstrated a high rate of 94% ART adherence, the study by Naik *et al*. showed a rate of 57%.([@ref12]) Therefore, the aim of this study is to systematically assess the rate of ART adherence across all studies conducted in India and the reasons for non-adherence (if any). We have performed a systematic review and metaanalysis to provide conclusive data on ART adherence in HIV/AIDS patients in India.

Materials and Methods {#sec1-2}
=====================

Literature search {#sec2-1}
-----------------

We searched the Medline (Pubmed) and Cochrane library database until August 2009 using combinations of the following text and MeSH terms: "Medication Adherence," "Patient Compliance," "antiretroviral therapy," "Antiretroviral Therapy, Highly Active," "HIV," "AIDS" and "India" for all years. No limits were applied on the basis of language, population or time period.

Inclusion criteria {#sec2-2}
------------------

Any prospective study or retrospective analysis assessing the rate of adherence to ART as a primary outcome in India was eligible for inclusion in the systematic review. Studies that were not related to HIV/AIDS or not related to adherence or focused on countries other than India were excluded.

Study selection and data extraction {#sec2-3}
-----------------------------------

Two reviewers (VA, AK) independently appraised the list of references and assessed the studies for their eligibility. Any disagreements were resolved by consensus. Data were extracted on definition of adherence, ART adherence estimates, study design, study population characteristics, recall period, study time frame and assessment method. We also extracted data on the methodological quality of the included studies.

For the purpose of metaanalysis, we first transformed the proportions into a quantity according to the Freeman-Tukey variant of the arcsine square root-transformed proportion.([@ref13]) The pooled proportion was calculated as a back-transform of the weighted mean of the transformed proportions using the random effects model. A formal statistical test for heterogeneity using the I^2^ test([@ref14]) was performed. We also explored heterogeneity and the robustness of the findings by conducting additional analyses according to study design, adherence assessment method and study region. The possibility of publication bias was also assessed using the Begg and Egger funnel plot method.([@ref15][@ref16]) This method has its limitations but is widely used to assess publication bias.([@ref17])

The metaanalysis was performed using STATA software.([@ref18]) The work was performed according to the PRISMA guidelines.([@ref19]) We evaluated the methodological quality of individual studies using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist.([@ref20]) Individual studies were evaluated to assess whether each item on the STROBE checklist was met or not met.

Results {#sec1-3}
=======

Identification of studies {#sec2-4}
-------------------------

The flow chart \[[Figure 1](#F1){ref-type="fig"}\] outlines the process of identification and selection of studies. The initial search yielded 25 citations, of which 17 were excluded for the reasons shown in [Figure 1](#F1){ref-type="fig"}. Accordingly, eight studies met the inclusion criteria and were included in the systematic review.

![Flow chart](IJCM-38-74-g001){#F1}

Characteristics of included studies {#sec2-5}
-----------------------------------

The eight included studies enrolled a total of 1666 participants (1322 male and 344 female participants). Characteristics of the included studies are summarized in [Table 1](#T1){ref-type="table"}. There were seven cross-sectional studies([@ref11][@ref12][@ref21][@ref22][@ref23][@ref24][@ref25]) and one retrospective chart analyses.([@ref26]) Three studies were conducted in southern India([@ref21][@ref24][@ref26]) and two each in western([@ref12][@ref25]) and north India.([@ref22][@ref23]) One study enrolled participants from western and northern India.([@ref11]) The average sample size was 208 (range: 53--310). The median age of participants in the included studies was 36 years (range: 24--42 years). The study by Shah *et al*.([@ref25]) used the Adult AIDS Clinical Trials group questionnaire for assessment of ART adherence while the study by Sarna *et al*.([@ref11]) used a semistructured questionnaire adapted from the Adult AIDS Clinical Trials group questionnaire.([@ref27]) The remaining studies (6/8) used unique data collection instruments designed by their respective study groups \[[Table 1](#T1){ref-type="table"}\].

###### 

Study characteristics

![](IJCM-38-74-g002)

Seventy-five percent (6/8) of the studies reported either median or range of duration of ART. However, only 50% (4/8) of the studies reported both median and range of ART duration.([@ref11][@ref12][@ref25][@ref26]) The length of ART regimens ranged from 1 month to 72 months across studies \[[Table 2](#T2){ref-type="table"}\]. Seventy-five percent (6/8) of the studies reported the recall period.([@ref11][@ref21][@ref22][@ref24][@ref25][@ref26]) The length of recall period varied from previous 4 days to lifetime recall \[[Table 2](#T2){ref-type="table"}\].

###### 

Treatment adherence data

![](IJCM-38-74-g003)

The definition of treatment adherence and associated cutoff values varied across the studies. Thirty-seven percent (3/8) of the studies([@ref12][@ref23][@ref24]) did not report the definition of treatment adherence. Sixty-two percent of studies (5/8) defined ART adherence. The study by Cauldbeck *et al*.([@ref21]) defined adherence as taking all medications as prescribed by the physician (all medications at a correct time on a correct day). The study by Wanchu and colleagues([@ref22]) specifically asked the participants if they forgot to take one or more dose(s) in the preceding 3 days or the last 1 and 4 weeks, and classified patients as being totally adherent (did not miss any dose) or non-adherent (missed at least one dose of medication in the preceding 4 weeks). The study by Sarna *et al*.([@ref11]) used a 4-day recall period as definition of adherence. In this study,([@ref11]) the mean 4-day adherence was calculated by dividing the number of pills actually taken by the number of pills needed to be taken for 4 days multiplied by 100, and then dichotomized as high adherence (\>90%) and low adherence (\<90%). The study by Shah and colleagues defined adherence as having taken ≥95% of the prescribed doses of medication over the past 4 days. Safren *et al*.([@ref26]) categorized adherence as regular versus irregular. Patients who took their prescribed doses daily and did not miss doses beyond one to two doses a month were categorized as "regular." Patients who missed doses at least once a week were identified as "irregular." Furthermore, patients who reported generally taking the medication but missed doses only recently (last week) were categorized as "recently missed some doses." Adherence was measured across various time periods, ranging from previous 4 days to lifetime adherence \[[Table 2](#T2){ref-type="table"}\].

Sixty-three percent (5/8) of the studies reported treatment regimens. All these 63% (5/8) studies reported use of non-nucleoside reverse-transcriptase inhibitors (NNRTIs). However, only two studies reported the details of NNRTI dosage.([@ref11][@ref23]) The quantity of pills consumed by study participants was reported only in 37% (3/8) of the studies.([@ref11][@ref21][@ref22]) The participants in the study by Caludbeck *et al*.([@ref21]) used two to more than 10 medication tablets per day, while patients in the study by Sarna *et al*.([@ref11]) consumed one to more than four tablets per day. Participants in the study by Wanchu *et al*.([@ref22]) consumed either two or three tablets per day. However, 99% (7/8) of the studies used the self-reporting method for assessment of treatment adherence, while only one study used the pill count method.([@ref24]) The study by George *et al*.([@ref24]) used the pill count method and followed three groups of patients for 6 months. Group 1 was given zidovudine, lamivudine and nevirapine, with a mean medication adherence of 90%; group 2 was given lamivudine, stavudine and nevirapine and achieved a mean medication adherence of 93%; and group 3 was given lamivudine, stavudine and efavirenz, and reported a mean medication adherence of 85%. In this study by George *et al*.,([@ref24]) the overall mean ART adherence showed regular improvement in the adherence rate over time among those who did not drop out of the study.

The impact of counseling on ART adherence was analyzed and reported in 37% (3/8) of the studies.([@ref21][@ref23][@ref25]) Specifically, Cauldbeck *et al*. reported that regular follow-up visits with the physician leads to improved ART adherence.([@ref21]) Shah *et al*. noted that pre-ART counseling had a positive impact on ART adherence.([@ref25]) However, Sharma *et al*. reported that counseling had no impact on ART adherence.([@ref23])

Methodological quality {#sec2-6}
----------------------

The methodological quality varied across the included studies. The methodological quality of the included study is summarized in [Table 3](#T3){ref-type="table"}. Sixty-two percent (5/8) of the studies([@ref11][@ref12][@ref21][@ref23][@ref24]) indicated the study\'s design with a commonly used term in the title or the abstract. Only 37% (3/8)([@ref11][@ref26][@ref28]) of the studies clearly defined all outcomes, exposures, predictors, potential confounders and effect modifiers. Only one study([@ref11]) described the calculations for sample size estimation. Moreover, none of the studies explained the methods used to address missing data, number of participants with missing data for each variable of interest and analytical techniques used to account for the sampling strategies. Only 37% (3/8) of the studies([@ref11][@ref23][@ref25]) reported the unadjusted estimates and confounder-adjusted estimates and their precision (95% confidence interval) and made clear which confounders were adjusted for and why they were included. Only 25% (2/8) of the studies([@ref24][@ref26]) reported the numbers of individuals at each stage of the study (e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up and analyzed). However, none of the studies employed a flow diagram depicting the follow-up of participants during the study period. All the included studies acknowledged and discussed the limitations of their study with potential sources of bias.

###### 

Methodological quality assessment (STROBE checklist)

![](IJCM-38-74-g004)

Outcomes {#sec2-7}
--------

### ART adherence {#sec3-1}

The main results, ART adherence definition and period of assessment are presented in [Table 2](#T2){ref-type="table"}. Data on overall ART adherence were extractable from all (8/8) studies. As shown in [Figure 2](#F2){ref-type="fig"}, the pooled proportion of ART adherence was 0.70 (95% CI: 0.59--0.81). However, there was a statistically significant heterogeneity for the outcome of overall ART adherence (I^2^ = 96.3%) among the included studies.

![Overall proportion of antiretroviral therapy adherence](IJCM-38-74-g005){#F2}

Additional analyses {#sec2-8}
-------------------

To assess the robustness of our findings and explore the reasons behind heterogeneity, we performed additional sensitivity analyses for the outcome of ART adherence. As shown in [Figure 3](#F3){ref-type="fig"}, there was no difference in estimates of ART adherence according to study design. The pooled proportion of ART adherence in studies employing a cross-sectional design was 0.72 (95% CI: 0.61, 0.83) compared with 0.59 (95% CI: 0.53, 0.66) in the retrospective study. However, the issue of heterogeneity within subgroups could not be assessed due to the limited number of prospective and retrospective studies (i.e., there were seven cross-sectional studies compared with only one retrospective study). Similarly, as shown in [Figure 4](#F4){ref-type="fig"}, subgroup analyses according to ART adherence assessment method also showed no difference. The pooled proportion of ART adherence was 0.71 (95% CI: 0.59, 0.82) in studies using the self-assessment method for the measurement of ART adherence versus 0.66 (95% CI: 0.58, 0.74) in studies using the pill count method. For similar reasons as in the case, study design assessment of heterogeneity within subgroups was not possible due to only one study using the pill count method for the assessment of ART adherence. Additional analysis according to the study regions (South India vs. North India vs. Western India) did not show any difference in the rates of ART adherence (data not shown).

![Antiretroviral therapy adherence by study design](IJCM-38-74-g006){#F3}

![Antiretroviral therapy adherence by method of assessment](IJCM-38-74-g007){#F4}

Reasons for non-adherence {#sec2-9}
-------------------------

The reasons for non-adherence to ART across the included studies are summarized in [Table 2](#T2){ref-type="table"}. Fifty percent (4/8) of the studies([@ref12][@ref22][@ref23][@ref26]) reported the cost of medication as the most common obstacle for treatment adherence. Patients reported not having access to sufficient amount of mediation in two studies as the reason for non-adherence to ART.([@ref21][@ref25]) Only one study reported adverse events as the most prevalent reason for non-adherence.([@ref24]) Similarly, only one study reported the patients being busy with other activities that lead to treatment non-adherence.([@ref11])

Publication bias {#sec2-10}
----------------

The assessment for publication bias in the included studies using the Begg and Egger funnel plot for the outcomes of ART adherence showed a skewed pattern, indicating a publication bias (*P* value = 0.003) \[[Figure 5](#F5){ref-type="fig"}\].

![Funnel plot for publication bias](IJCM-38-74-g008){#F5}

Discussion {#sec1-4}
==========

This is the first systematic review and meta-analysis addressing the issue of ART adherence in India, which has one of the largest populations of HIV/AIDS patients in the world.([@ref1]) The results from this systematic review and metaanalysis show that overall adherence to ART in India is around 70%, which may be inadequate for the effective control of viremia. These results also show that achieving the desirable ART adherence of more than 75--80% with NNRTI regimen is often challenging in the Indian context. In addition to the well-recognized factors of cost, complexity and adverse events, lifestyle factors and issues in the patient--provider relationship may adversely influence adherence in Indian patients.([@ref29]) As shown in the results, the study by George *et al*.([@ref24]) cited adverse events as the major reason for non-adherence. However, this study had three ART regimens groups (zidovudine, lamivudine, nevirapine vs. lamivudine, stavudine, nevirapine vs. lamivudine, stavudine, efavirenz), and the rate of adverse events was similar across all treatment groups, excluding association of any particular ART regimen with increased risk for non-adherence due to adverse events. Cost was noted as the most common reason, followed by adverse events for non-adherence in this systematic review. Nevertheless, the study by Sarna *et al*. contradicted the finding of cost as a reason for non-adherence. The patients enrolled in the study by Sarna *et al*. treated at a private facility reported an adherence rate of 94%, despite the fact that this is expensive in the Indian context. A subgroup of patients in this study receiving HIV treatment at no cost had poor adherence to ART. These findings differ from a previously reported systematic review/metaanalysis of ART intervention programs in a resource-poor setting.([@ref30]) The results from this systematic review/metaanalysis showed that provision of medications free of charge was associated with a higher probability of achieving higher adherence.([@ref30]) Similarly, ART adherence studies by Kumarasamy *et al*. and Wanchu *et al*. conducted in India also showed the association of high cost of ART as a barrier to ART adherence.([@ref10][@ref22]) In addition, none of the studies mentioning cost as a barrier to ART adherence explain in detail what constitutes cost. There are multiple costs, including the cost of the medication, the cost of travel and access to physicians or cost of diagnostic tests as a barrier to ART adherence. Moreover, where the Government of India is providing ART for over 0.3 million individuals in approximately 239 ART centers,([@ref2]) only 50% (4/8) studies included in this review discussed ART cost in the context of subsidized ART compared with ART offered at private clinics.([@ref11][@ref22][@ref23][@ref24])

The lowest ART treatment adherence rate was reported by Sharma *et al*.([@ref23]) with 59% adherence over 16 months. The low ART adherence as reported in this study can be explained by two factors: this study enrolled only injecting drug users, and used the self-reported assessment to measure ART adherence. Previous studies assessing adherence in injecting drug users have shown to have higher rates of non-adherence compared with the general HIV/AIDS population.([@ref31][@ref32][@ref33]) Additionally, studies have shown the self-reported assessment method to be unreliable in assessing ART adherence.([@ref34][@ref35][@ref36]) The variability of the study methodology, specifically variations in assessment of adherence, may explain the observed heterogeneity in the included studies. Overall, our findings are in line with a previous systematic review and metaanalysis on ART adherence enrolling patients in Sub Saharan Africa \[ART adherence: 77% (95% CI 68--85%)\].([@ref37]) There are patients in both (Indian and Sub Saharan African) settings that have suboptimal adherence and that factors beyond poverty, such as forgetfulness, severity of adverse events and the level of complexity of the drug regimen, play an important role.([@ref37])

The results from this systematic review also show that the quality of reporting of the included studies is poor. For example, several key elements of a study were either not reported or reported in a fashion that cannot be used for informed decision-making. Only few of the studies (12.5%) reported analytical methods taking account of sampling strategy or report the numbers of individuals at each stage of the study (25%), which is a key to interpret the findings and assess the generalizability of the results. The results from this systematic review also show a lack of sociocultural acclimatization of the tools used to assess ART adherence. For example, only 37% (3/8) of the studies([@ref11][@ref12][@ref21]) reported any efforts to adapt the questionnaire used for data collection to the study population. However, none of the included studies reported use of any qualitative techniques to pilot test data collection strategies to ensure cultural relevance and validity. The lack of these formative evaluations could have unfavorable ramifications in a country like India with diverse social and economic settings. That is, the instrument validated for assessment of ART adherence in one study population in India may not prove to be useful to assess treatment adherence in other populations. In general, these studies investigated numerous socioeconomic factors correlated to ART adherence. They largely maintain the claim that in India, HIV-infected adults' socioeconomic context with the treatment-related factors (e.g., adverse events) play a key role in ART adherence. However, none of the included studies linked these socioeconomic and treatment-related variables to a culturally appropriate model for ART adherence. Therefore, the information from these studies limits the end users ability to use this information in any useful way to improve ART adherence. Possibly due to the issues mentioned above, the adherence rate did not differ across the geographical regions in India. Another area of concern is the use of varying ART duration (range: 1--72 months) and recall periods (range: 4 days to lifetime). Moreover, studies using multiple recall periods did not report adherence estimates for each period, limiting our ability to compare adherence estimates and recommend an optimum recall period.

This systematic review has limitations. We performed searches of only standardized databases (Medline and Cochrane library) and, therefore, might have missed either unpublished studies or articles reported in the grey literature. Different interpretations of what constitutes adherence versus non-adherence makes the generalizability of the results limited. We were not able to conduct sensitivity analyses to evaluate possible relationships between different regimens and patient characteristics and adherence (e.g., presumed higher adherence among patients with lower pill burden vs. higher pill burden), because this information was rarely available among the identified studies. Similarly, we were unable to analyze the impact of counseling on ART adherence in a metaanalysis as the data were scarcely reported. Finally, it is possible that most of the studies in this systematic review might be overestimating adherence levels, due mainly to the fact that seven out of eight included studies relied only on self-reported adherence--a measure known to overestimate patients' true adherence levels.

In the future, researchers should standardize adherence definitions and use a standardized recall period, such as the 7-day recall, which is shown to have has better sensitivity.([@ref35]) Our efforts to increase access to ART must be combined with efforts to design new and effective strategies of improving adherence in a resource-limited setting. The report found the overall adherence to be poor in comparison with documented effective adherence for HIV/AIDS treatment. There is abundant variation in the definition of adherence and what constitutes "optimal adherence" across the studies with poor reporting regarding data collection methods. These facts prohibit extrapolating the results to guide policies to improve ART adherence.

This first systematic review and metaanalysis assessing the adherence to ART in the HIV-infected population in India highlights lower overall adherence to ART in India. However, the quality of included studies is poor and needs improvement in analysis and reporting, such as impact of counseling on ART adherence. Similarly, future researchers should explore the association of various ART cost attributes and ART adherence in detail. In conclusion, this systematic review shows an urgent need to improve the quality of reporting, such as standardized adherence definition, threshold, period of measurement, etc. to be established, where data can be easily extracted, interpreted and used for informing programs and policies to improve ART adherence.
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